Search

Your search keyword '"Donfracesco, A."' showing total 5 results
Start Over Author "Donfracesco, A."
5 results on '"Donfracesco, A."'

2. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Author

Innocenza Palaia, Daniela Musio, Alessia Romito, P. Benedetti Panici, C. Donfracesco, Ludovico Muzii, Ilaria Piacenti, Laura Vertechy, Angela Musella, Vincenzo Tombolini, Claudia Marchetti, and F. De Felice

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Organoplatinum Compounds, gynecologic, Antineoplastic Agents, 03 medical and health sciences, ovarian cancer, platinum resistant, recurrence, tyrosine-kinases inhibitors, 0302 clinical medicine, Clinical Trials, Phase II as Topic, Recurrence, Internal medicine, medicine, Humans, Multicenter Studies as Topic, Radiology, Nuclear Medicine and imaging, Molecular Targeted Therapy, Protein Kinase Inhibitors, Peritoneal Neoplasms, Platinum resistant, Randomized Controlled Trials as Topic, Gynecology, Ovarian Neoplasms, Settore MED/06 - ONCOLOGIA MEDICA, business.industry, Carcinoma, General Medicine, medicine.disease, Gynecological cancer, Neoplasm Proteins, 030104 developmental biology, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Treatment Outcome, Clinical evidence, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, Ovarian cancer, Tyrosine kinase
Abstract

For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

Published
2015

3. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Author

Marchetti, Claudia, Palaia, I., De Felice, F., Musella, A., Donfracesco, C., Vertechy, L., Romito, A., Piacenti, I., Musio, D., Muzii, L., Tombolini, V., Benedetti Panici, P., Marchetti C. (ORCID:0000-0001-7098-8956), Marchetti, Claudia, Palaia, I., De Felice, F., Musella, A., Donfracesco, C., Vertechy, L., Romito, A., Piacenti, I., Musio, D., Muzii, L., Tombolini, V., Benedetti Panici, P., and Marchetti C. (ORCID:0000-0001-7098-8956)

Abstract

For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

Published
2016

5. Deferoxamine followed by cytoxan, etoposide, carboplatin and thiotepa (D-CECaT protocol) in patients with advanced neuroblastoma

Author

M. T. Di Tullio, Alberto Garaventa, L Cordero di Montezemolo, S. Bagnulo, Modesto Carli, B. De Bernardi, A. Donfracesco, Antonia Mancini, and G. Deb

Subjects
Oncology, medicine.medical_specialty, business.industry, ThioTEPA, medicine.disease, Deferoxamine, Internal medicine, Neuroblastoma, Internal Medicine, Medicine, In patient, Etoposide carboplatin, business, medicine.drug
Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results